BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marcellin P, Zoulim F, Hézode C, Causse X, Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP, Bourlière M, Riachi G, Zarski JP, Cadranel JF, Tilliet V, Stern C, Pétour P, Libert O, Consoli SM, Larrey D. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France. Dig Dis Sci 2016;61:3072-83. [PMID: 26821154 DOI: 10.1007/s10620-015-4027-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Lee HY, Oh H, Park CH, Yeo YH, Nguyen MH, Jun DW. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis. World J Gastroenterol 2019; 25(23): 2961-2972 [PMID: 31249453 DOI: 10.3748/wjg.v25.i23.2961] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR, Lee TY. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat 2021;28:1579-86. [PMID: 34464999 DOI: 10.1111/jvh.13603] [Reference Citation Analysis]
3 Tavakolpour S, Darvishi M, Mirsafaei HS, Ghasemiadl M. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond). 2018;50:95-106. [PMID: 29020844 DOI: 10.1080/23744235.2017.1384957] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
4 Liang X, Gao Z, Xie Q, Zhang J, Sheng J, Cheng J, Chen C, Mao Q, Zhao W, Ren H, Tan D, Niu J, Chen S, Pan C, Tang H, Wang H, Mao Y, Jia J, Ning Q, Xu M, Wu S, Li J, Zhang X, Zhang W, Xiong C, Hou J. Long-term efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B: 5-year results. Hepatol Int. 2019;13:260-269. [PMID: 30977033 DOI: 10.1007/s12072-019-09943-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lemoine M, Shimakawa Y, Njie R, Taal M, Ndow G, Chemin I, Ghosh S, Njai HF, Jeng A, Sow A. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. Lancet Glob Health. 2016;4:e559-e567. [PMID: 27443781 DOI: 10.1016/s2214-109x(16)30130-9] [Cited by in Crossref: 88] [Cited by in F6Publishing: 47] [Article Influence: 22.0] [Reference Citation Analysis]
6 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
7 Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H; ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' Group. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Aliment Pharmacol Ther 2020;52:500-12. [PMID: 32583915 DOI: 10.1111/apt.15901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Siakavellas S, Goulis J, Manolakopoulos S, Triantos C, Gatselis N, Tsentemidou E, Kranidioti H, Ζisimopoulos Κ, Τsoulas C, Dalekos G, Papatheodoridis G. Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. Ann Gastroenterol 2021;34:73-9. [PMID: 33414625 DOI: 10.20524/aog.2020.0525] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Tsai HJ, Chuang YW, Lee SW, Wu CY, Yeh HZ, Lee T. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. Aliment Pharmacol Ther 2018;47:1673-81. [DOI: 10.1111/apt.14682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
10 Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study. J Antimicrob Chemother 2021;76:3009-19. [PMID: 34458919 DOI: 10.1093/jac/dkab294] [Reference Citation Analysis]
11 Zheng S, Liu L, Lu J, Zhang X, Shen H, Zhang H, Xue Y, Lin L. Efficacy and safety of tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B virus infection: A 2-year prospective study. Medicine (Baltimore) 2019;98:e17590. [PMID: 31626130 DOI: 10.1097/MD.0000000000017590] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
12 Bielen R, Robaeys G, Schelfhout S, Monbaliu D, Van der Merwe S, Pirenne J, Nevens F. Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogs for patients at risk of renal failure after liver transplantation: a prospective single center cohort study. Transpl Int 2018;31:503-9. [PMID: 29359868 DOI: 10.1111/tri.13112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Buti M, Riveiro-Barciela M, Esteban R. Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. Clin Liver Dis 2021;25:725-40. [PMID: 34593150 DOI: 10.1016/j.cld.2021.06.003] [Reference Citation Analysis]
14 Wang T, Smith DA, Campbell C, Mokaya J, Freeman O, Salih H, McNaughton AL, Cripps S, Várnai KA, Noble T, Woods K, Collier J, Jeffery K, Davies J, Barnes E, Matthews PC. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. BMC Infect Dis 2021;21:610. [PMID: 34174833 DOI: 10.1186/s12879-021-06226-0] [Reference Citation Analysis]
15 Rachel M, Barbara C, Murphy C, Komujuni C, Nyakato P, Ocama P, Lamorde M, Easterbrook P, Ratanshi RP. Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting. Hepatol Med Policy 2018;3:3. [PMID: 30288326 DOI: 10.1186/s41124-017-0030-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Grossi G, Viganò M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int 2017;37:45-51. [DOI: 10.1111/liv.13291] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
17 Boyd A, Dezanet LNC, Lacombe K. Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review. Viruses 2021;13:1341. [PMID: 34372547 DOI: 10.3390/v13071341] [Reference Citation Analysis]
18 Boyd A, Canini L, Gozlan J, Lascoux-Combe C, Miailhes P, Fonquernie L, Girard PM, Lacombe K. Development of anti-hepatitis B surface (HBs) antibodies after HBs antigen loss in HIV-hepatitis B virus co-infected patients. J Clin Virol 2017;95:55-60. [PMID: 28869890 DOI: 10.1016/j.jcv.2017.08.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Jeng WJ, Chien RN, Liaw YF. Fibrosis in patients with chronic hepatitis B and minimally raised ALT during tenofovir therapy. Lancet Infect Dis 2021;21:910-1. [PMID: 34174230 DOI: 10.1016/S1473-3099(21)00317-0] [Reference Citation Analysis]
20 Kuppili PP, Selvakumar N, Menon V. Sickness Behavior and Seasonal Affective Disorder: An Immunological Perspective of Depression. Indian J Psychol Med 2018;40:266-8. [PMID: 29875535 DOI: 10.4103/IJPSYM.IJPSYM_232_17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
21 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
22 He L, Ye X, Ma J, Li P, Jiang Y, Hu J, Yang J, Zhou Y, Liang X, Lin Y, Wei H. Antiviral therapy reduces rebleeding rate in patients with hepatitis B-related cirrhosis with acute variceal bleeding after endotherapy. BMC Gastroenterol 2019;19:101. [PMID: 31226942 DOI: 10.1186/s12876-019-1020-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Chen XF, Fan YN, Si CW, Yu YY, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Xu JH. Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World J Clin Cases 2021; 9(18): 4690-4699 [PMID: 34222435 DOI: 10.12998/wjcc.v9.i18.4690] [Reference Citation Analysis]
24 Ahn HJ, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK. Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea. PLoS One 2017;12:e0170362. [PMID: 28114428 DOI: 10.1371/journal.pone.0170362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
25 Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Min IS, Lee CH, Shin IS, Lee NE, Son HS, Kim SB, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim IH. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate. Gut Liver 2019;13:93-103. [PMID: 30400723 DOI: 10.5009/gnl18183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
27 Liang RY, Xu JH, Si CW, Wang S, Shang J, Yu ZJ, Mao Q, Xie Q, Zhao W, Li J, Gao ZL, Wu SM, Tang H, Cheng J, Chen XY, Zhang WH, Wang H, Xu ZN, Wang L, Dai J, Yu YY. A randomized, double-blind, double-dummy, controlled, multicenter study of Qingzhong (tenofovir disoproxil fumarate) vs Viread for the treatment of chronic hepatitis B: First-stage results at week 48. Medicine (Baltimore). 2019;98:e16778. [PMID: 31415381 DOI: 10.1097/md.0000000000016778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Wu Z, Ma AL, Xie Q, Zhang XQ, Cheng J, Zhang DZ, Wang GQ, Zhao H. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT. Clin Res Hepatol Gastroenterol 2021;45:101463. [PMID: 32571749 DOI: 10.1016/j.clinre.2020.05.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T, Nomura T, Tani J, Yoneyama H, Morishita A, Oryu M, Himoto T, Nishitsuji H, Shimotohno K, Omata M, Masaki T. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. Int J Mol Sci 2018;19:E1940. [PMID: 30004437 DOI: 10.3390/ijms19071940] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38 Suppl 1:84-89. [PMID: 29427500 DOI: 10.1111/liv.13641] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
31 Luo J, You X, Chong Y, Wu Y, Gong J, Jie Y, Li X, Xi S, Zhang Z, Zhang Y, Xie D, Li Z, Li X. Efficacy of long-term treatment with tenofovir in Chinese nucleos(t)ide-naïve chronic hepatitis B patients regardless of baseline viral load. Exp Ther Med 2019;18:260-8. [PMID: 31258661 DOI: 10.3892/etm.2019.7547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241 [PMID: 28261380 DOI: 10.4254/wjh.v9.i5.227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
33 Lu JC, Liu LG, Lin L, Zheng SQ, Xue Y. Incident hepatocellular carcinoma developing during tenofovir alafenamide treatment as a rescue therapy for multi-drug resistant hepatitis B virus infection: A case report and review of the literature. World J Clin Cases 2018; 6(13): 671-674 [PMID: 30430123 DOI: 10.12998/wjcc.v6.i13.671] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
34 Cohen D, Shimakawa Y, Ndow G, Sow A, Tamba S, Njie R, Lo G, Ghosh S, Toure-Kane C, Ka M, Mboup S, Okeke E, Toure S, Diop M, D'Alessandro U, Taylor-Robinson S, Mendy M, Zoulim F, Thursz MR, Lemoine M, Chemin I. [Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study]. Med Sci (Paris) 2019;35:431-9. [PMID: 31115326 DOI: 10.1051/medsci/2019076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
36 Jia J, Li Y, Wei C, Guo R, Xu H, Jia Y, Wu Y, Li Y, Wei Z, Qi X, Li Z, Gao X. Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection. Exp Ther Med 2019;17:4730-40. [PMID: 31086607 DOI: 10.3892/etm.2019.7482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
37 Lin Y, Liu Y, Ding G, Touqui L, Wang W, Xu N, Liu K, Zhang L, Chen D, Wu Y, Bai G. Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads. Sci Rep. 2018;8:15514. [PMID: 30341345 DOI: 10.1038/s41598-018-33833-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
38 Li X, Luo J, Zhu C, Wu Y, Li Z, Jie Y, Zhang Y, Lin G, Li X, Zhang Y, Shu X. Efficacy of tenofovir disoproxil fumarate switch therapy in chronic hepatitis B patients with suboptimal response to adefovir-based combination therapy. Exp Ther Med 2019;17:1196-205. [PMID: 30679993 DOI: 10.3892/etm.2018.7081] [Reference Citation Analysis]
39 Choe JY, Ko JS, Choe BH, Kim JE, Kang B, Lee KJ, Yang HR. Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B. J Korean Med Sci 2018;33:e11. [PMID: 29215820 DOI: 10.3346/jkms.2018.33.e11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
40 Cuenca-Gómez JÁ, Lozano-Serrano AB, Cabezas-Fernández MT, Soriano-Pérez MJ, Vázquez-Villegas J, Estévez-Escobar M, Cabeza-Barrera I, Salas-Coronas J. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice. BMC Infect Dis 2018;18:568. [PMID: 30428845 DOI: 10.1186/s12879-018-3469-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Blanchet M, Sinnathamby V, Vaillant A, Labonté P. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells. Antiviral Res 2019;164:97-105. [PMID: 30771404 DOI: 10.1016/j.antiviral.2019.02.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
42 Riveiro-barciela M, Tabernero D, Calleja JL, Lens S, Manzano ML, Rodríguez FG, Crespo J, Piqueras B, Pascasio JM, Comas C, Gutierrez ML, Aguirre A, Suárez E, García-samaniego J, Rivero M, Acero D, Fernandez-bermejo M, Moreno D, Sánchez-pobre P, de Cuenca B, Moreno-palomares JJ, Esteban R, Buti M. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. Dig Dis Sci 2017;62:784-93. [DOI: 10.1007/s10620-017-4448-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
43 Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical Implications of Hepatitis B Virus RNA and Covalently Closed Circular DNA in Monitoring Patients with Chronic Hepatitis B Today with a Gaze into the Future: The Field Is Unprepared for a Sterilizing Cure. Genes (Basel) 2018;9:E483. [PMID: 30301171 DOI: 10.3390/genes9100483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kar P, Sengupta A. Synthetic therapeutics for the treatment of hepatitis B during pregnancy. Expert Opin Pharmacother 2018;19:1771-8. [PMID: 30273073 DOI: 10.1080/14656566.2018.1527313] [Reference Citation Analysis]